Omentin-1 vs DSIP
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and DSIP (Delta Sleep-Inducing Peptide) — benefits, dosing, side effects, research data, and where to buy.
| Property | Omentin-1 | DSIP |
|---|---|---|
| Category | Diabetes & Metabolic | Performance |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Delta Sleep-Inducing Peptide |
| Molecular Weight | ~35 kDa | 848.8 Da |
| Half-Life | hours | ~15-25 minutes |
| Amino Acids | 313 | 9 |
| Typical Dose | No approved human dose; research use only | 100-200 mcg |
| Route | IV|SC | SC / IV / Intranasal |
| Purity | ≥98% | — |
| Studies Count | 82 | 74 |
| Research Status | Pre-clinical | Pre-clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
DSIP Benefits
- ✓Promotes deep delta wave sleep
- ✓Normalizes disrupted sleep patterns
- ✓Reduces cortisol and stress response
- ✓Pain modulating effects
- ✓Antioxidant properties
Omentin-1 Dosing
not established|not established
DSIP Dosing
Standard: 100-200 mcg SC or IV, 30-60 min before bed|Cycle: 10-14 days, 5-7 days off|Chronic insomnia: 100 mcg daily for 2-3 weeks|Can be combined with Ipamorelin pre-bed
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
DSIP Side Effects
- ⚠Common (Mild): Morning grogginess initially, mild headache
- ⚠Rare: Vivid dreams, temporary appetite changes
- ⚠Generally very well tolerated
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
DSIP
DSIP has moderate clinical evidence from European studies. Human trials show improved sleep quality and normalized sleep-wake cycles. Also studied for alcohol and opiate withdrawal. Unique mechanism distinct from traditional sleep aids.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.